Skip to content

Psychedelic-assisted therapy: all studies

Page 59 of 294: studies 581 to 590 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy

Frontiers in Psychiatry March 20, 2019 Ben Sessa, David Nutt, Laurie Higbed 141 citations

This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA...

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy

Journal of Psychoactive Drugs March 15, 2019 Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al. 207 citations

Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as...

Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD

Journal of Psychoactive Drugs March 8, 2019 William P. Barone, Jerome Beck, Michiko Mitsunaga-Whitten et al. 63 citations

We present select findings from a long-term follow-up qualitative study of MDMA-assisted psychotherapy for veterans, firefighters, and police officers suffering from chronic, treatment-resistant PTSD. Semi-structured qualitative interviews were conducted at participants' one-year follow-up after a recently completed phase 2 clinical trial. Available interviews from 19 of 24 participants were...

DOI: 10.1080/02791072.2019.1580805 (opens in new tab) MDMA Thematic analysis Qualitative research Interpretative phenomenological analysis +4

Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens

Journal of Psychedelic Studies February 25, 2019 Jenna Varley 4 citations

Psychedelics have been investigated for their therapeutic applications in end-of-life care as early as 1960. Recently, there have been four main groups conducting clinical trials for either lysergic acid diethylamide or psilocybin for the treatment of anxiety and depression in patients with terminal illnesses. The recent trials have higher methodological quality and demonstrate the profound...

DOI: 10.1556/2054.2019.005 (opens in new tab) Psilocybin Death anxiety Distress Psychotherapist +4

Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?

Journal of Psychedelic Studies February 21, 2019 Zuzana Postránecká, Čestmír Vejmola, Filip Tylš 6 citations

Psychedelic research has been associated with the Czech Republic since the early 19th century and, after a long period of involuntary dormancy, it has recently gained new opportunities to follow up on its roots and evolve. This article briefly describes the history of psychedelic research in the Czech Republic, summarizes the role of the UN Drug Conventions, and discusses the Czech and...

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis

International Journal of Drug Policy February 10, 2019 Elena Argento, Kenneth W. Tupper, M. Eugenia Socias 17 citations

The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmacotherapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for innovative interventions...

DOI: 10.1016/j.drugpo.2018.11.006 (opens in new tab) Opioid use disorder Fentanyl Psychological intervention Pharmacotherapy +3

The Trials of Psychedelic Therapy: LSD Psychotherapy in America by Matthew Oram

Bulletin of the history of medicine 2019 Nicolas Rasmussen

Reviewed by: The Trials of Psychedelic Therapy: LSD Psychotherapy in America by Matthew Oram Nicolas Rasmussen Matthew Oram. The Trials of Psychedelic Therapy: LSD Psychotherapy in America. Baltimore: Johns Hopkins University Press, 2018. xiv + 269 pp. Ill. $49.95 (978-1-4214-2620-4). The colorful history of the hallucinogen LSD has attracted the attention of numerous historians of medicine,...

DOI: 10.1353/bhm.2019.0041 (opens in new tab) Psychotherapist Hallucinogen Psychodynamics Clinical trial +1

[Neurotrophic mechanisms of psychedelic therapy].

Biologie aujourd'hui 2019 Rémi Corne, Raymond Mongeau 7 citations

Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules....

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Journal of Psychopharmacology December 1, 2018 Marcela Ot'Alora G, Jim Grigsby, Bruce Poulter et al. 232 citations

Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Twenty-eight...

DOI: 10.1177/0269881118806297 (opens in new tab) Full text (opens in new tab) Serotonin 3,4-Methylenedioxymethamphetamine MDMA Oxytocin Posttraumatic stress disorder +16